<p>鲜为人知的药企 <strong>脑再生科技</strong>（NASDAQ：<strong>RGC</strong>）周二股价飙升，但并无明显催化剂。然而，其独特的业务特点——专注于传统中医治疗神经认知障碍，可能引起了投机者的注意。虽然中医为医疗效用带来一些希望，RGC 股票仍然是一项高度投机的投资。</p>
<p>周二交易日接近尾声时，脑再生科技股价涨幅约为 345%。自本文撰写时，RGC 股票的热度导致纳斯达克今天多次停止交易。截至目前，强制停牌次数已达 20 次。</p>
<p>没有任何新闻事件可以解释情绪提升。根据 Fintel 数据，空头头寸仅占流通股的 0.06%，空头头寸比率仅为 1.64 天。因此，不太可能是空头压力推动了 RGC 股票的上涨。因此，可能是对脑再生科技几乎独特业务的兴趣催化了股价上涨。</p>
<p>虽然中医的首次记录实践可追溯至公元前 200 年，但很少有专注于该领域的上市公司。除了 RGC 股票外，<strong>中国盛虹药业</strong>（NASDAQ：<strong>SXTC</strong>）是少数几家提供中医产品的企业之一。</p>
<h2>RGC 股票有一些乐观的理性基础</h2>
<p>要强调 RGC 股票的风险性，过去 52 周几乎没有盈利。这表明长期持有者遭受了巨大的亏损。但也不公平地宣称脑再生科技和中医实践完全是投机的。</p>
<p>首先，中医有悠久的历史。这并不是说该实践不会产生副作用，因为已经注意到了不良反应。然而，一些患者可能更愿意接受传统解决方案的自然基础。</p>
<p>此外，对中医的初步研究显示，这种疗法可以引发脑波活动的积极变化，从而改善注意缺陷多动障碍（ADHD）患者的行为挑战，如多动、冲动和学习困难。这些研究与脑再生科技的核心关注点一致，该公司专注于 ADHD 和自闭症谱系障碍。</p>
<p>此外，中医市场正在增长。根据 Persistence Market Research 的数据，2022 年全球中医行业产生的收入达到 287 亿美元。到 2033 年，该生态系统的价值可能达到 496 亿美元，意味着复合年增长率为 5.1%。</p>
<p>但应注意，中医缺乏严格的标准化研究和测试。因此，投资者应极度谨慎地对待 RGC 股票。</p>
<p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外，InvestorPlace 不会发表关于市值低于 1 亿美元或每天交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的游乐场。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者注意风险。</p>
<p><em><strong>阅读更多：</strong> 低价股——</em> <em>如何在不受骗的情况下获利</em></p>
<p><em>在本文发布日期，Josh Enomoto 在本文中提到的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com</em> <em>发布准则</em>。</p>
<p>_在本文发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何持仓。</p>
<p>Josh Enomoto 曾是索尼电子的高级业务分析师，曾协助与财富全球 500 强公司达成重要合同。在过去几年中，他为投资市场以及法律、建筑管理和医疗保健等其他行业提供了独特而关键的见解。在 Twitter 上关注他 @EnomotoMedia。</p>
<p>生物技术，医疗保健</p>
<p>低价股</p>

脑再生科技

<p>脑再生科技（RGC）股票因其在传统中医治疗神经认知障碍方面的专业化而价值显著上涨。然而，这仍然是一项高度投机的投资。公司独特的业务模式可能引起了投资者的兴趣，但由于中医药领域缺乏标准化的研究和测试，投资者应谨慎对待。中医药市场正在增长，但 RGC 股票几乎没有盈利。这些信息属于与商业相关的信息和股价涨跌信息类别</p>

<p>Little-known drug manufacturer <strong>Regencell Bioscience</strong> (NASDAQ: <strong>RGC</strong>) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it’s possible that the exceptionally distinct business profile — specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders — caught the attention of speculators. While TCM offers some hope for medical utility, RGC stock remains a highly speculative investment.</p>
<div class="lb-trans"><p>鲜为人知的药企 <strong>脑再生科技</strong>（NASDAQ：<strong>RGC</strong>）周二股价飙升，但并无明显催化剂。然而，其独特的业务特点——专注于传统中医治疗神经认知障碍，可能引起了投机者的注意。虽然中医为医疗效用带来一些希望，RGC 股票仍然是一项高度投机的投资。</p>
</div><p>Heading into the final stretch of the Tuesday session, Regencell gained about 345% of equity value. Naturally, the fervor over RGC stock caused the <strong>Nasdaq</strong> to halt trading multiple times today. As of this writing, the number of forcible halts amounted to 20 occurrences.</p>
<div class="lb-trans"><p>周二交易日接近尾声时，脑再生科技股价涨幅约为 345%。自本文撰写时，RGC 股票的热度导致纳斯达克今天多次停止交易。截至目前，强制停牌次数已达 20 次。</p>
</div><p>No news item appears to be responsible for the sentiment boost. Per Fintel, the short interest sits at only 0.06% of the float, with the short interest ratio coming in at only 1.64 days to cover. It’s unlikely, then, that short-squeeze speculation sparked the lift in RGC stock. Therefore, it’s possible that interest in Regencell’s almost-unique business catalyzed the jump higher.</p>
<div class="lb-trans"><p>没有任何新闻事件可以解释情绪提升。根据 Fintel 数据，空头头寸仅占流通股的 0.06%，空头头寸比率仅为 1.64 天。因此，不太可能是空头压力推动了 RGC 股票的上涨。因此，可能是对脑再生科技几乎独特业务的兴趣催化了股价上涨。</p>
</div><p>While the first documented practice of TCM dates back to 200 BCE, it’s rare to find publicly traded companies that specialize in the field. Aside from RGC stock, <strong>China SXT Pharmaceuticals</strong> (NASDAQ: <strong>SXTC</strong>) is one of a small handful of enterprises that offer TCM products.</p>
<div class="lb-trans"><p>虽然中医的首次记录实践可追溯至公元前 200 年，但很少有专注于该领域的上市公司。除了 RGC 股票外，<strong>中国盛虹药业</strong>（NASDAQ：<strong>SXTC</strong>）是少数几家提供中医产品的企业之一。</p>
</div><h2>RGC Stock Enjoys Some Rational Basis for Optimism</h2>
<div class="lb-trans"><h2>RGC 股票有一些乐观的理性基础</h2>
</div><p>To underscore the wildness of RGC stock, it’s barely profitable over the past 52 weeks. That goes to show prospective investors the magnitude of red ink that long-term stakeholders have suffered. Still, it would also be unfair to declare that Regencell and the underlying TCM practice is completely speculative.</p>
<div class="lb-trans"><p>要强调 RGC 股票的风险性，过去 52 周几乎没有盈利。这表明长期持有者遭受了巨大的亏损。但也不公平地宣称脑再生科技和中医实践完全是投机的。</p>
</div><p>For one thing, TCM has a long history of use. That’s not to say that the practice doesn’t generate side effects because adverse reactions have been noted. However, some patients may feel more comfortable with the natural fundamentals of traditional solutions.</p>
<div class="lb-trans"><p>首先，中医有悠久的历史。这并不是说该实践不会产生副作用，因为已经注意到了不良反应。然而，一些患者可能更愿意接受传统解决方案的自然基础。</p>
</div><p>In addition, preliminary research into TCM shows that such therapeutics can spark positive changes in brainwave activity, thus improving behavioral challenges such as hyperactivity, impulsivity and learning difficulties in subjects affected by attention deficit hyperactivity disorder (ADHD). Such research is aligned with Regencell’s core focus, which targets ADHD and autism spectrum disorder.</p>
<div class="lb-trans"><p>此外，对中医的初步研究显示，这种疗法可以引发脑波活动的积极变化，从而改善注意缺陷多动障碍（ADHD）患者的行为挑战，如多动、冲动和学习困难。这些研究与脑再生科技的核心关注点一致，该公司专注于 ADHD 和自闭症谱系障碍。</p>
</div><p>Further, the TCM market is a growing one. According to Persistence Market Research, global revenue generated by the sector landed at $28.7 billion in 2022. By 2033, the ecosystem could be worth $49.6 billion, implying a compound annual growth rate of 5.1%.</p>
<div class="lb-trans"><p>此外，中医市场正在增长。根据 Persistence Market Research 的数据，2022 年全球中医行业产生的收入达到 287 亿美元。到 2033 年，该生态系统的价值可能达到 496 亿美元，意味着复合年增长率为 5.1%。</p>
</div><p>Still, it should be noted that TCM lacks rigorous standardized research and testing. Therefore, investors should approach RGC stock with extreme caution.</p>
<div class="lb-trans"><p>但应注意，中医缺乏严格的标准化研究和测试。因此，投资者应极度谨慎地对待 RGC 股票。</p>
</div><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong> With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.</em></p>
<div class="lb-trans"><p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外，InvestorPlace 不会发表关于市值低于 1 亿美元或每天交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的游乐场。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者注意风险。</p>
</div><p><em><strong>Read More:</strong> Penny Stocks —</em> <em>How to Profit Without Getting Scammed</em></p>
<div class="lb-trans"><p><em><strong>阅读更多：</strong> 低价股——</em> <em>如何在不受骗的情况下获利</em></p>
</div><p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，Josh Enomoto 在本文中提到的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com</em> <em>发布准则</em>。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在本文发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何持仓。</p>
</div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p>
<div class="lb-trans"><p>Josh Enomoto 曾是索尼电子的高级业务分析师，曾协助与财富全球 500 强公司达成重要合同。在过去几年中，他为投资市场以及法律、建筑管理和医疗保健等其他行业提供了独特而关键的见解。在 Twitter 上关注他 @EnomotoMedia。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物技术，医疗保健</p>
</div><p>Penny Stocks</p>
<div class="lb-trans"><p>低价股</p>
</div>

今天脑再生科技（RGC）股票怎么了？